AIMS: To measure the effectiveness of antidepressants for adolescents and young adults with co-occurring depression and substance use disorder. DESIGN, SETTING AND PARTICIPANTS: Meta-analysis of randomized controlled clinical trials. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science and PsychINFO was conducted (from 1970 to 2013). Prospective, parallel groups, double-blind, controlled trials with random assignment to an antidepressant or placebo on young patients (age ≤ 25 years) who met diagnostic criteria of both substance use and unipolar depressive disorder were included. Five trials were selected for this analysis and included 290 patients. MEASUREMENTS: Our efficacy outcome measures were depression outcomes (dichotomous and continuous measures) and substance-use outcomes (change of frequency or quantity of substance-use). Secondary analysis was conducted to access the tolerability of antidepressant treatment. FINDINGS: For dichotomous depression outcome, antidepressants group was significantly more effective than placebo group [risk ratio (RR) = 1.21; 95% confidence interval (CI) 1.01-1.45], with low heterogeneity (I(2) = 0%). Although no statistically significant effects for continuous depression outcome [standardized mean differences (SMD) = -0.13; 95% CI, -0.55 to 0.30] were found with moderate heterogeneity (I(2) = 63%), subgroup analysis showed that the medicine group with a sample size of more than 50 showed statistically significant efficacy compared with the placebo group (SMD -0.53, 95% CI -0.82 to -0.25). Moreover, there was no significant difference for substance-use outcomes and tolerability outcomes between the medication and placebo groups. CONCLUSIONS: Antidepressant medication has a small overall effect in reducing depression in young patients with combined depressive and substance-use disorders, but does not appear to improve substance use outcomes.
AIMS: To measure the effectiveness of antidepressants for adolescents and young adults with co-occurring depression and substance use disorder. DESIGN, SETTING AND PARTICIPANTS: Meta-analysis of randomized controlled clinical trials. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science and PsychINFO was conducted (from 1970 to 2013). Prospective, parallel groups, double-blind, controlled trials with random assignment to an antidepressant or placebo on young patients (age ≤ 25 years) who met diagnostic criteria of both substance use and unipolar depressive disorder were included. Five trials were selected for this analysis and included 290 patients. MEASUREMENTS: Our efficacy outcome measures were depression outcomes (dichotomous and continuous measures) and substance-use outcomes (change of frequency or quantity of substance-use). Secondary analysis was conducted to access the tolerability of antidepressant treatment. FINDINGS: For dichotomous depression outcome, antidepressants group was significantly more effective than placebo group [risk ratio (RR) = 1.21; 95% confidence interval (CI) 1.01-1.45], with low heterogeneity (I(2) = 0%). Although no statistically significant effects for continuous depression outcome [standardized mean differences (SMD) = -0.13; 95% CI, -0.55 to 0.30] were found with moderate heterogeneity (I(2) = 63%), subgroup analysis showed that the medicine group with a sample size of more than 50 showed statistically significant efficacy compared with the placebo group (SMD -0.53, 95% CI -0.82 to -0.25). Moreover, there was no significant difference for substance-use outcomes and tolerability outcomes between the medication and placebo groups. CONCLUSIONS: Antidepressant medication has a small overall effect in reducing depression in young patients with combined depressive and substance-use disorders, but does not appear to improve substance use outcomes.
Authors: Xinyu Zhou; Sarah E Hetrick; Pim Cuijpers; Bin Qin; Jürgen Barth; Craig J Whittington; David Cohen; Cinzia Del Giovane; Yiyun Liu; Kurt D Michael; Yuqing Zhang; John R Weisz; Peng Xie Journal: World Psychiatry Date: 2015-06 Impact factor: 49.548
Authors: André Q C Miguel; Clarice S Madruga; Hugo Cogo-Moreira; Rodolfo Yamauchi; Viviane Simões; Ariadne Ribeiro; Claudio J da Silva; Andrew Fruci; Michael McDonell; Sterling McPherson; John M Roll; Ronaldo R Laranjeira Journal: Exp Clin Psychopharmacol Date: 2017-12 Impact factor: 3.157
Authors: Kelli Scott; Sara J Becker; Sarah A Helseth; Ian J Saldanha; Ethan M Balk; Gaelen P Adam; Kristin J Konnyu; Dale W Steele Journal: Fam Pract Date: 2022-03-24 Impact factor: 2.290
Authors: Joseph A Delaney; Robin M Nance; Bridget M Whitney; Frederick L Altice; Xinyuan Dong; Maria Esther Perez Trejo; Mika Matsuzaki; Faye S Taxman; Geetanjali Chander; Irene Kuo; Rob Fredericksen; Lauren N Strand; Joseph J Eron; Elvin Geng; Mari M Kitahata; William C Mathews; Kenneth Mayer; Richard D Moore; Michael S Saag; Sandra Springer; Redonna Chandler; Shoshana Kahana; Heidi M Crane Journal: J Acquir Immune Defic Syndr Date: 2018-11-01 Impact factor: 3.731
Authors: Jianfei Wang; Xu Dong; Li Cao; Yangyang Sun; Yu Qiu; Yi Zhang; Ruoqiong Cao; Mihai Covasa; Li Zhong Journal: J Int Med Res Date: 2016-11-11 Impact factor: 1.671